facilitating distinction among the different types of aspartic proteinases.
Thus, while considerable progress has been made in elucidating the structure, activity and importance (biological and commercial) of the aspartic proteinases, much remains to be learned about the distinctions in molecular architecture and how these are reflected in the functions of the various enzymes. Inhibitors (naturally occurring and synthetic) have permitted detailed biochemical and crystallographic investigations to be made but an understanding of the selectivity of such inhibitors may be of just as much importance for the design and synthesis of specific inhibitors for use therapeutically in controlling individual aspartic proteinases (e.g. renin). These and other aspects will be discussed in the articles which follow this introductory review.
Renin is an aspartic proteinase synthesized mainly in the juxtaglomerular cells of the kidney. It cleaves its substrate angiotensinogen to give the decapeptide angiotensin I, which is then converted to the effector hormone of the renin-angiotensin system, angiotensin 11, by a carboxydipeptidase, converting enzyme. Angiotensin I1 has many effects concerned with the control of electrolyte balance and blood pressure.
The specificity of renin for one peptide bond in its substrate and the fact that it is active at pH 7.4 makes it unusual among aspartic proteinases, although it has features in common with other members of the group. Certain regions of primary sequence are homologous, especially DAVID M. JONES,? GORDON D. MCINTYRE,* JAVIER around the two active-site aspartic acid residues. Knowledge of the primary structure, deduced from cDNA cloning of the human renin gene, has allowed predictions to be made concerning the three-dimensional structure of the enzyme (Blundell et al., 1983; Imai et al., 1983; Soubrier et al., 1983) .
Like pepsin and cathepsin D, renin is synthesized as an enzymically inactive precursor which is cleaved, probably by a serine proteinase, to give the active enzyme. The prosequence shows differences compared with that of pepsinogen and this may be related to the different mechanism of activation (Imai et al., 1983; Soubrier et al., 1983; McIntyre et al., 1984b) .
The substrate specificity of renin was first investigated at a molecular level by Skeggs et al. (1957) , who showed that it requires the (6-13)-octapeptide at the N-terminus of angiotensinogen in order to cleave the scissile bond, which is Leu-10-Leu-] 1 in horse angiotensinogen and Leu-10-Val-11 in the human protein (Tewksbury et al., 1978) . After the discovery of the sequence, substrate analogue inhibitors of renin were synthesized by substitution of amino acid residues in the octapeptide sequence Vol. 13 (Kokubu et al., 1968; Burton et al., 1975; Boger et al., 1983) . A peptide described by Burton et al. (1980) was an effective renin inhibitor when tested in primates and in man.
A different approach was used by Parry et al. (1972) , who modified the scissile peptide bond to produce 'isosteric' compounds that mimic the hypothetical transition-state. Such isosteric inhibitors have proved useful in the study of the enzyme and may be of therapeutic interest.
Inhibition of the renin-substrate reaction
Effect of substituting the scissile peptide bond. Synthetic octapeptides corresponding to the sequence of residues in positions 6-13 of horse (peptide A) and human (peptide H112) angiotensinogens were synthesized. These peptides act as weak inhibitors (Table 1 ) when tested with human or dog renin and the homologous angiotensinogen. The first isosteric compounds synthesized, H-76 and H-77, were based on the (6-1 3)-octapeptide sequence of horse angiotensinogen (peptide A), with a 'reduced isostere' at the scissile bond, and were more active against dog than human renin (Szelke et al., 19826) . When the reduced isostere was inserted into the human octapeptide sequence, the resultant compound, H-113, was 1500-fold more active than the parent peptide (Szelke et al., 1982a) . The structure of these peptides is shown in Table 1 , which also shows the effect of inserting 'keto' and 'hydroxy' isosteres at the scissile peptide bond of the human (6-13)octapeptide. Insertion of the hydroxy isostere at the scissile bond produced a compound, H-194, 100 000-fold more potent than the unmodified peptide. Substitution of the naturally occurring amino acid, statine, for Leu-10 to give the peptide H-176 resulted in good inhibition despite the extra carbon atom introduced into the backbone chain . This indicates the importance of the hydroxyl group in the affinity of the inhibitor for the enzyme and confirms its role in the transition-state during hydrolysis of the peptide. Interestingly, the keto isostere H-272 is a relatively poor inhibitor.
Other residues of the substrate, apart from those in P1 and P1', are important in determining the potency of inhibition. The residues concerned with species-specificity appear to be 11, 12 and 13 of the (6-13)-octapeptide, i.e. PI', Pz' and P3'. These vary between species, while the angiotensin I sequence is highly conserved. The speciesspecificity of the reduced isostere was investigated by substituting 'equine' for 'human' residues in the P1p, Pz'
and P3' positions, as shown in Table 2 . Substitution of His-13 (human) by Tyr-13 (horse) to give peptide H-116 led to little change in the potency of the inhibitor against human renin but to a 14-fold improvement in the action against dog renin. Substitution of Ile-12 by Val-12 to give peptide H-117 led to an approx. threefold loss of potency against human renin but to a sixfold increase against dog renin, while substitution of Val-1 1 by Leu-1 1 (peptide H-76) led to a further threefold loss of potency against human renin but to a 60-fold improvement against dog renin. Thus dog renin appears to be more exacting in its requirement for the correct 'animal' sequence than human renin does for the human sequence. These findings agree with earlier reports that human renin will cleave dog or ox substrate, but animal renins will not act on human substrate (Poulsen et al., 1976; Leckie et al., 1983) . Burton et al. (1980) showed that the addition of proline to the N-terminus and lysine to the C-terminus of their peptide inhibitor improved its action against human renin. It can be seen (Table 1) that the same modification applied to several reduced isosteres also improved the inhibition (Szelke et al., 1982a) . The effect appears to be due to the addition of proline, giving a residue in the P6 position as in peptide H-148 (Table l) , rather than to the presence of lysine at P4f as in peptide H-165 (Table 1) . The same modification had little effect on compounds containing the statine substitution, as shown by peptide H-189 when compared with peptide H-176, or the hydroxy isostere, as shown by peptide H-263 compared with H-194 (Table 1) . However, when a butyloxycarbonyl group was placed at the N-terminus in an analogue of human angiotensinogen containing the keto isostere or the hydroxy isostere, improvement of the inhibition was noted. The hydroxy isostere, H-261, is one of the most potent renin inhibitors synthesized.
Isosteric renin inhibitors as affinity ligands. The isosteric
inhibitor H-77 has been used to purify human renin in one step and for the purification of the probable human renin precursor (McIntyre et al., 1984b) .
Renin and its precursor are present in very low concentration in the kidney. Values ranging from 7 to 3400 ng/g of cortex are found in kidney tissue from patients with renal artery stenosis in whom the renin levels are likely to be higher than normal. In the same kidneys, the concentration of the inactive precursor ranged from 9 to 11 10 ng/g of tissue. The small amount of human material available has precluded the preparation of sufficient enzyme for conventional amino acid sequencing or for crystallographic studies. The M, of human renin is 40000 (Slater et al., 1978; Galen et al., 1979; Yokosawa e f al., 1980) . The M, of the probable precursor was 48 000 by polyacrylamide-gel electrophoresis in the presence of sodium dodecyl sulphate. The active enzyme and the enzymically inactive precursor were compared by preparing partial Staphylococcus aureus V8 proteinase digests and the resulting peptides were analysed by h.p.1.c. Both proteins contained similar peptides but the trace from the precursor showed additional peaks which could represent peptides derived from the prosequence (McIntyre et al., 1 9 8 4~) .
Inhibition of renin in man
The action of some isosteric compounds has been studied in vivo, most recently in man (Webb et al., 1983) .
The reduced isostere H-142 was tested by infusion into nine Na+-deplete normal volunteers. Three studies were done in each subject. An intravenous infusion of glucose for 1 h was followed by an infusion of either glucose or H-142 at 1 or 2.5 mg/h per kg for 30min, followed by glucose for 1.5 h. Fig. 1 shows the results with the 2.5 mg/h per kg infusion. Administration of H-142 resulted in a fall in circulating angiotensin I and angiotensin I1 concentrations and in diastolic blood pressure. A fall in the enzymic activity of renin measured in the plasma was observed during infusion of the inhibitor. However, when the immunoreactive renin protein was measured, by the method of Galen et al. (1984) , an increase was noted, suggesting that an increase in renin secretion had occurred. The production of renin by the kidney is under negative feedback control by angiotensin 11. It is also stimulated by a fall in blood pressure. Either mechanism could account for the increase in renin production observed. Heart rate increased slightly during infusion of the inhibitor. After the infusion of H-142 at 2.5 mg/h per kg ended, blood angiotensin I increased to 158% of basal, plasma angiotensin I1 to 286% of basal and renin enzymic activity to 389% of basal. However, there was no significant increase of blood pressure above basal values.
Conclusion
The work described above shows that substitution of the scissile peptide bond by isosteres that mimic the transitionstate produces effective renin inhibitors. Inhibition depends Vol. 13 not only on the type of isostere but also on the amino acid residues in the peptide sequence adjacent to the scissile peptide bond. Since renin requires a long peptide, synthesis of effective low-M, inhibitors depends on further studies to discover which binding sites are the most important. In the case of the isosteric inhibitors, the effectiveness of amino acid substitutions at sites remote from the scissile bond appears to vary with the type of isostere occupying the scissile bond. This may indicate that the conformation of the peptide chain in the binding cleft is different with different inhibitors.
The effectiveness of the isosteric inhibitors in vivo indicates that there may be a therapeutic role for renin inhibitors. Inhibitors of converting enzyme are already in clinical use. Our results indicate that the rise in renin concentration during short-term infusion was not sufficient to overcome the effect of the inhibitor, and that a rise in blood pressure did not occur when the infusion was stopped despite an 'overshoot' increase in plasma angiotensin I1 concentration. A longer-acting, orally active compound may be effective in hypertensive people.
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Sufficient is known of the sequences and three-dimensional structures of aspartic proteinases t o establish their membership of a common structural family (Subramanian et al., 1977; Tang et al., 1978; Shewale & Tang, 1984; Hemmings et al., 1985) . This includes aspartic proteinases of microbial origin as well as extra-and intra-cellular enzymes in eukaryotes. Crystallographic studies have identified a common bi-lobal structure, each lobe contributing one of the two active site aspartic acid residues (Andreeva & Gustchina, 1979; Tang et al., 1978) . Further, each structurally equivalent lobe contains two similar halves, also related by a dyad (Blundell et aL, 1979) . Internal sequence homology supports these findings, reflecting the view that aspartic proteinases are constructed of four units of common evolutionary origin which may therefore be termed 'folding units'. It is a matter of some interest to know whether, Abbreviations used: DAG, diazoacetylglycine ethyl ester; GdmC1, guanidinium chloride. after the considerable mutation and adaptation of the ancestral unit, these still retain the ability to fold kinetically in an independent manner, constituting intermediates on the folding pathway.
In contrast to pepsin, the three-dimensional structure of the intracellular proteinase cathepsin D has not yet been determined but the amino acid sequence has recently been elucidated (Shewale & Tang, 1984) . The sequence has resolved one of the main problems of incorporating this enzyme into the aspartic proteinase family (that of its higher apparent Mr) by showing that the protein component is larger than that of pepsin by only 12 amino acid residues, these being inserted at various points throughout the sequence. Secondly, there is now no doubt of the homology with pepsin and renin, 32.7% of the residues being identical in these three enzymes. It is therefore pertinent to enquire as to what degree of similarity in behaviour exists between cathepsin D and its better-characterized siblings.
Denaturation may be defined as the modification of protein conformation by perturbing non-covalent interactions to a degree which leads to measurable changes in parameters such as enzyme activity and spectroscopic properties. It may range, therefore, from complete unfolding into a form essentially lacking in intramolecular noncovalent interactions on the one hand to a relatively minor
